Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F17%3AA1801RYI" target="_blank" >RIV/61988987:17110/17:A1801RYI - isvavai.cz</a>
Alternative codes found
RIV/00843989:_____/17:E0106713
Result on the web
<a href="http://dx.doi.org/10.1038/leu.2017.122" target="_blank" >http://dx.doi.org/10.1038/leu.2017.122</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1038/leu.2017.122" target="_blank" >10.1038/leu.2017.122</a>
Alternative languages
Result language
angličtina
Original language name
Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes
Original language description
Autologous stem cell transplantation (ASCT) is a standard treatment for eligible multiple myeloma (MM) patients, but many patients will relapse after ASCT and require subsequent therapy. The proteasome inhibitor carfilzomib is approved for relapsed or refractory MM (RRMM). In phase 3 trials, carfilzomib-based regimens (ASPIRE, carfilzomib-lenalidomide-dexamethasone; ENDEAVOR, carfilzomib-dexamethasone) demonstrated superior progression-free survival (PFS) compared with standard therapies for RRMM (ASPIRE: lenalidomide-dexamethasone; ENDEAVOR, bortezomib-dexamethasone). This subgroup analysis of ASPIRE and ENDEAVOR evaluated outcomes according to prior ASCT status. In total, 446 patients in ASPIRE and 538 in ENDEAVOR had prior ASCT. Median PFS was longer for carfilzomib-based regimens vs non-carfilzomib-based regimens for patients with prior ASCT (ASPIRE: 26.3 vs 17.8 months (hazard ratio (HR) = 0.68); ENDEAVOR: not estimable vs 10.2 months (HR = 0.61)), those with one prior line of therapy that included ASCT (ASPIRE: 29.7 vs 17.8 months (HR = 0.70); ENDEAVOR: not estimable vs 11.2 months (HR = 0.46)), and those without prior ASCT (ASPIRE: 26.4 vs 16.6 months (HR = 0.76); ENDEAVOR: 17.7 vs 8.5 months (HR = 0.43)). Overall response rates also favored the carfilzomib-based regimens. No new safety signals were detected. This analysis suggests that carfilzomib-based treatment may lead to improvement in PFS and response rates regardless of prior transplant status. Further evaluation is warranted.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2017
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
LEUKEMIA
ISSN
0887-6924
e-ISSN
1476-5551
Volume of the periodical
31
Issue of the periodical within the volume
12
Country of publishing house
GB - UNITED KINGDOM
Number of pages
12
Pages from-to
2630-2641
UT code for WoS article
000417177100012
EID of the result in the Scopus database
2-s2.0-85032905845